Castle Biosciences, Inc.
CSTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.31 | 0.59 | -0.08 | -0.27 |
| FCF Yield | 4.94% | -3.33% | -7.71% | -2.08% |
| EV / EBITDA | 16.96 | -10.99 | -8.63 | -20.65 |
| Quality | ||||
| ROIC | 1.52% | -16.74% | -21.41% | -7.12% |
| Gross Margin | 81.87% | 79.53% | 76.64% | 83.18% |
| Cash Conversion Ratio | 3.56 | 0.10 | 0.62 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | 34.32% | 32.69% | 29.81% | 21.96% |
| Free Cash Flow Growth | 289.85% | 59.30% | -110.48% | -539.30% |
| Safety | ||||
| Net Debt / EBITDA | -2.45 | 1.85 | 1.88 | 8.78 |
| Interest Coverage | 15.03 | -6,179.73 | -5,361.29 | -40,079.00 |
| Efficiency | ||||
| Inventory Turnover | 7.40 | 5.66 | 8.04 | 7.83 |
| Cash Conversion Cycle | 63.78 | 44.73 | 53.96 | 54.93 |